Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces Share Repurchase Program

March 1, 2019 • 4:00 PM EST

Tonix Pharmaceuticals Announces New Board Member, James Treco

February 19, 2019 • 4:30 PM EST

Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference

February 4, 2019 • 8:00 AM EST

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion

January 2, 2019 • 7:00 AM EST

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

December 18, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering

December 11, 2018 • 4:00 PM EST

Tonix Pharmaceuticals Prices $15,000,000 Public Offering

December 7, 2018 • 10:35 AM EST

Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes

November 29, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

November 27, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

November 9, 2018 • 7:30 AM EST

« Previous
1
2
3
4
5
6
7
8
9
10
...28
Next »

Show All

News / Press Releases : Press Releases